Avenzo gets FDA permission to proceed with Phase I/II trials of an EGFR/HER3 bispecific antibody and a CDK4 inhibitor in select solid tumors.

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

Located at the system's hospital in St. George, Utah, the clinic intends to offer T-cell collection closer to home.

NEW YORK – CureDuchenne Ventures has made a $1 million initial investment in Entos Pharmaceuticals, supporting its development of a genetic medicine for Duchenne muscular dystrophy (DMD).

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.

The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

NEW YORK – Sarepta Therapeutics on Wednesday said that the UK's Medicines & Healthcare Products Regulatory Agency has lifted the clinical hold on a Phase III study of its Duchenne muscular dystrophy ...

Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.